肝细胞癌

为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？

Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?

装载 miR-17-5p 抑制剂的工程化 CAR-T 细胞外囊泡抑制肝细胞癌进展

Engineered CAR-T extracellular vesicles loaded with miR-17-5p inhibitor suppress hepatocellular carcinoma progression.

本研究表明，靶向NKG2D的CAR-T EV通过直接肿瘤细胞毒性和恢复NK细胞功能发挥联合抗HCC活性，为HCC提供了一种新的免疫治疗策略。

PSMA1、PSMA5 和 PSMB2 作为预后生物标志物，并与 HCC 中肿瘤浸润白细胞相关

PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC.

当前对周围血免疫细胞表型在癌症治疗耐药中作用的认识

Current Insights into the Role of Peripheral Blood Immune Cell Phenotypes in Resistance to Cancer Therapies.

多组学驱动的精准策略克服胃肠道恶性肿瘤中 CAR-T 治疗的局限性

Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies.

NSUN2 介导的 m(5)C 修饰的代谢重编程通过限制 NK 细胞介导的细胞毒性促进肝细胞癌进展

Metabolic Reprogramming of NSUN2-Mediated m(5)C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-M

系统性治疗背景下 TACE-RFA 与单一疗法治疗复发性肝细胞癌的比较评估：一项倾向性评分匹配分析

Comparative evaluation of TACE-RFA versus monotherapies on a background of systemic therapy for recurrent hepatocellular carcinoma: a propensity score

对于接受 Lenvatinib 和 PD-1 抑制剂同步治疗的 rHCC 患者，序贯 TACE-RFA 治疗相比局部单一治疗提供了深远且独立的无进展生存期获益，且未增加患者不适。优越的局部肿瘤控制证明了预期的围手术期资源消耗初始增加是合理的。

胸腺肽α-1 在肿瘤治疗中的作用：免疫调节机制、临床应用及转化前景

Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.

共载黄芪甲苷 IV 与雷帕霉素的骨髓间充质干细胞来源外泌体纳米载体靶向调控肝细胞癌 PI3K/Akt/mTOR 通路

Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR p

RAP@AST-IV/EXO NC 通过联合抑制 PI3K/Akt/mTOR 和诱导线粒体凋亡，代表了一种有前景且具有生物相容性的靶向 HCC 治疗策略。

血小板在肝细胞癌免疫微环境中的作用及其临床前景：一篇综合综述

The role of platelets in the hepatocellular carcinoma immune microenvironment and their clinical prospects: a comprehensive review.